Dowiedzieć się o najlepszych cenach i klinikach w terapii celowanej w Izraelu w 2026 roku

Choosing the best targeted therapy doctor in Israel requires identifying specialists with international fellowship training and clinical trial leadership. Prioritize board-certified oncologists at JCI-accredited centers like Sourasky Medical Center. These experts often hold memberships in the European Society of Medical Oncology (ESMO).

• International training: Top doctors like Prof. Ofer Merimsky trained at renowned centers like Institut Gustave Roussy.
• Research leadership: Select doctors like Dr. David Sarid who act as principal investigators for clinical trials.
• Sub-specialization focus: Dr. Tamar Sapra focuses on gynecological cancers while Dr. Fredi Aviv specializes in oncohematology.
• Genomic expertise: Dr. Ari Raphael pioneers national genomic medicine programs for precise treatment matching.

Bookimed Expert Insight: Data shows that choosing a doctor who moderates a Molecular Tumor Board, such as Dr. Ari Raphael, provides a significant advantage. These specialists don't just prescribe standard drugs but specialize in NGS interpretation. This ensures that targeted therapies are matched to specific genetic mutations rather than just the cancer type.

Patient Consensus: Patients note that working with doctors who run clinical trials often provides access to new protocols. They emphasize choosing specialists in Tel Aviv who participate in multidisciplinary boards for better-tailored treatments. Many felt more confident when their doctor had published research on their specific biomarker.

Israeli oncologists lead targeted therapy through rapid clinical translation of genomic research and unique diagnostic accuracy. Specialists like Dr. Ari Raphael and Prof. Ofer Merimsky integrate advanced liquid biopsies and molecular profiling into routine care. This precision approach often corrects initial diagnoses for up to 91% of complex international cases.

• Molecular profiling: Experts use comprehensive genomic sequencing to identify specific treatable mutations in tumors.
• Early drug access: Patients receive novel targeted medications through extensive phase I-III clinical trial programs.
• Liquid biopsy leadership: Doctors monitor cancer markers via blood tests, reducing the need for invasive tissue biopsies.
• Specialized fellowships: Leading oncologists hold advanced training from Memorial Sloan-Kettering, Royal Marsden, and Institut Gustave Roussy.

Bookimed Expert Insight: A distinct advantage in Israel is the integration of genomic medicine into national health initiatives. Dr. Ari Raphael leads the National Genomic Medicine Initiative, which allows for earlier access to T-cell sequencing and cfDNA monitoring. This structural collaboration means patients at clinics like Sourasky Medical Center receive experimental protocols years before they reach global markets.

Patient Consensus: Patients often mention being surprised by the depth of genomic testing available compared to their home countries. Many note that the innovative approach to rare mutations gave them treatment options they were previously told did not exist. They describe feeling a sense of relief when specialized protocols were tailored specifically to their genetic markers.

You can receive a second opinion from leading targeted therapy specialists in Israel through remote video consultations or in-person visits. Top oncologists at JCI-accredited centers like Sourasky Medical Center (Ichilov) and Assuta Medical Center provide genomic-guided treatment plans and access to early-phase clinical trials.

• Specialized expertise: Prof. Ofer Merimsky at Sourasky Medical Center is a foremost expert in sarcoma and lung cancer.
• Genomic medicine: Dr. Ari Raphael leads national genomic initiatives and specializes in liquid biopsies for precision oncology.
• Consultation options: Specialists offer online reviews with fees ranging from $750 to $1,050 for senior experts.
• Advanced therapies: Specialists like Dr. Pelles Sharon provide targeted treatments, SIRT therapy, and HIPEC for complex cases.

Bookimed Expert Insight: Israeli oncology centers often provide faster access to rare mutation analysis compared to many European facilities. Data shows that specialists like Dr. Ari Raphael at Sourasky Medical Center (Ichilov) integrate computational biology with clinical trials. This allows patients to receive personalized therapy recommendations based on the latest NGS genomic profiling techniques quickly.

Patient Consensus: Patients note that Israeli doctors often find treatment options or clinical trials missed by their local physicians. Many were surprised by how quickly they could arrange a video call to discuss rare mutations. Some Mentioned that sending pathology slides in advance is necessary to get the most out of the consultation.

Targeted therapy doctors in Israel use personalized testing to match treatments to a tumor's specific genetic profile. Leading specialists utilize advanced genomic sequencing and molecular profiling to identify actionable mutations. This precision approach is standard at JCI-accredited centers like Sourasky Medical Center and Assuta Medical Center.

• Genomic profiling: Specialists use Next-Generation Sequencing (NGS) to scan hundreds of cancer-related genes simultaneously.
• Liquid biopsies: Experts like Dr. Ari Raphael use blood-based DNA tests to monitor treatment response.
• Oncotesting: Doctors apply specific tests like Oncotype DX to determine if chemotherapy is necessary.
• Targeted biomarkers: Oncologists test for PD-L1 and HER2 markers to predict immunotherapy and drug success.

Bookimed Expert Insight: Israel's leadership in genomic medicine is driven by specialists who also lead national research initiatives. For example, Dr. Ari Raphael at Sourasky Medical Center heads the Israeli National Genomic Medicine Initiative (PSIFAS). Patients often benefit from this integration, as doctors who participate in these national programs frequently serve as primary investigators for international clinical trials.

Patient Consensus: Patients note that while genetic testing is common, it is helpful to ask for comprehensive profiling early in the diagnosis. Many found that private facilities provide test results much faster than public options. They emphasize that's it's important to have a doctor who clearly explains how these test results change the treatment plan.

Patients seeking targeted therapy in Israel can expect seamless communication as English is the standard language for oncology consultations. Top specialists at facilities like Sourasky Medical Center undergo extensive training in the US, UK, and Europe, ensuring they are fluent in medical English.

• International training: Many oncologists completed fellowships at institutions like Memorial Sloan-Kettering and Oxford.
• Global board memberships: Surgeons actively participate in the American Society of Clinical Oncology (ASCO).
• Academic leadership: Leading doctors publish research in English-language journals and lecture at international universities.
• Research collaboration: Specialists lead global clinical trials, requiring constant English communication with international partners.

Bookimed Expert Insight: A notable pattern among Israel's top oncologists is their dual role as researchers and clinicians. For instance, Dr. Ari Raphael and Dr. David Sarid lead national genomic initiatives and clinical trials, which necessitates daily professional-level English. Patients often find that these doctors explain complex molecular results more clearly than general practitioners because of their academic backgrounds.

Patient Consensus: Patients note that consultations are typically conducted entirely in English without any language barriers. They describe feeling relieved that physicians speak directly to them rather than relying on translation apps or intermediaries. Many were surprised at how easily they could discuss intricate treatment details and side effects during their appointments.